Page 1

TFF PHARMACEUTICALS FOR IMMEDIATE RELEASE EXHIBIT 99.1 TFF Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update Additional Data Readouts and Initiation of Pivotal Trials for Inhaled Tacrolimus and Voriconazole Programs Expected in 2H 2021 Multiple Ascending Dose ( MAD ) Study Demonstrates Inhaled Tacrolimus Inhalation Powder Achieves Blood Levels Sufficient Immunosuppression Formation of Scientific Advisory Board to Enable Continued Innovation and Clinical Development Partnerships with Pharma , Academic Institutions and Government Continue to Advance Conference Call and Webcast Scheduled Today , Thursday , August 12 , 2021 , at 4:30 pm EDT Efficacious AUSTIN , TX — August 12 , 2021 —TFF Pharmaceuticals , Inc. ( NASDAQ : TFFP ) , a clinical - stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing ( TFF ) technology platform , today reported financial results for the second quarter ended June 30 , 2021 , and also provided an update on recent corporate and clinical developments . The Company will discuss the clinical , corporate and financial highlights on a conference call and webcast , scheduled today , Thursday , August 12 , 2021 , at 4:30 pm EDT . " As we advance both our internal programs and external partnerships , TFF Pharmaceuticals continues to demonstrate the transformative potential of our proprietary Thin Film Freezing ( TFF ) drug delivery platform to improve upon pharmacokinetic and clinical profiles of currently approved therapies , while also formulating novel small molecule and biologic - based therapeutics that address serious unmet medical need , " said Glenn Mattes , President and CEO of TFF Pharmaceuticals .